SCHEMBL1639999

SCHEMBL1639999

O=C1C(c2ccccc2)C(=O)N(c2ccccc2)C(=O)N1c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
GFER P55789 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
MGLL Q99685 1/20 0.45
GAA P10253 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTR2B P41595 1/20 0.43
MAOA P21397 1/20 0.43
POLB P06746 1/20 0.43
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15131571 0.89 F2 (0.55) ALDH1A1GFERMEN1KMT2AMGLL
SCHEMBL15131563 0.85 HSP90AA1 (0.50) ALDH1A1GFERMEN1KMT2AMGLL
SCHEMBL15131565 0.85 MAPT (0.57) ALDH1A1GFERMEN1KMT2AMGLL
SCHEMBL17717922 0.82 NPC1 (0.38) ALDH1A1GFERMEN1KMT2ALMNA
SCHEMBL15131560 0.82 EP300 (0.50) ALDH1A1MEN1KMT2AMGLLLMNA
SCHEMBL1639996 0.81 ALDH1A1 (0.42) ALDH1A1GFERMEN1KMT2AMGLL
SCHEMBL15131564 0.79 MEN1 (0.45) ALDH1A1MEN1KMT2AMGLLGAA
SCHEMBL15131573 0.79 NPSR1 (0.51) ALDH1A1MEN1KMT2AGAATP53
SCHEMBL3498051 0.78 ALDH1A1 (0.50) ALDH1A1GFERMEN1KMT2AMGLL
SCHEMBL208852 0.77 MEN1 (0.44) ALDH1A1GFERMEN1KMT2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081576-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES Taro Pharmaceuticals North America, Inc. (KY) 2009-07-29 EP claimed
WO-2008066704-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) 2008-06-05 WO claimed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US claimed
CN-1291720-C Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2006-12-27 CN claimed
EP-1485101-A4 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMA IND (IL) 2006-04-12 EP claimed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US claimed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN claimed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP claimed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US claimed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO claimed
CN-104744732-B Optical film, polarizing plate and liquid crystal display device using the same, and compound 富士胶片株式会社 2020-03-03 CN disclosed
US-10240033-B2 Optical film and method for manufacturing same, polarization plate, and liquid crystal display apparatus FUJIFILM CORPORATION (JP) 2019-03-26 US disclosed
US-20170322358-A1 POLARIZING PLATE, FRONT PANEL OF DISPLAY DEVICE, DISPLAY APPARATUS, SUBSTRATE OF TOUCH PANEL, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL FUJIFILM CORPORATION (JP) 2017-11-09 US disclosed
US-20170322358-A1 POLARIZING PLATE, FRONT PANEL OF DISPLAY DEVICE, DISPLAY APPARATUS, SUBSTRATE OF TOUCH PANEL, RESISTIVE FILM-TYPE TOUCH PANEL, AND CAPACITANCE-TYPE TOUCH PANEL FUJIFILM CORPORATION (JP) 2017-11-09 US disclosed
WO-2016190105-A1 POLYIMIDE FILM, METHOD FOR PRODUCING POLYIMIDE FILM, FLEXIBLE PRINTED BOARD, SUBSTRATE FOR FLEXIBLE DISPLAYS, FRONT PLATE FOR FLEXIBLE DISPLAYS, LED LIGHTING DEVICE AND ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE コニカミノルタ株式会社 2016-12-01 WO disclosed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US disclosed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN disclosed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP disclosed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US disclosed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates MTNR1B, GABRB3, GABBR1 ALDH1A1 790/4885GFER 3151/4885MEN1 1891/4885
US-20030187005-A1 Non-sedating barbituric acid derivatives GABRA5, GABRA1, GABRA3 ALDH1A1 283/4885GFER 3680/4885MEN1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.